Expression and clinical significance of serum anterior gradient-2 in prostate cancer patients

Abstract

Objective To determine the level of serum anterior gradient-2 (AGR2) in prostate cancer, and investigate its clinical application value. Methods The serum levels of AGR2 were detected by enzyme-linked immuno sorbent assay (ELISA) in 46 patients with prostate cancer, 20 patients with benign prostatic hyperplasia (BPH) and 20 cases of healthy control. Results ①The levels of serum AGR2 in patients with prostate cancer were obviously higher than that in BPH group and health control group (P 0.05). ②The level of serum AGR2 after treatment was significantly lower than that before treatment (P<0.01). Before operation in patients with prostate cancer, the level of preoperative serum AGR2 was higher than that in post-operation (P<0.01). The level of serum AGR2 before endocrine therapy was higher than after endocrine therapy in patients with prostate cancer (P<0.01). ③The levels of serum AGR2 in prostate cancer were positively correlated with clincal stage and Gleason pathologic stage (P<0.05). The level of AGR2 was positively correlated with PSA (P<0.01). ④The area under the ROC curve (AUC) of AGR2 was 0.792, when the best threshold was 13.75 ng/mL, sensitivity rate was 71.7%, specificity rate was 75%. Conclusions The level of serum AGR2 in prostate cancer is higher, positively correlated with the clinical stage and Gleason pathologic stage. It may be play certain clinical significance in diagnosis, malignant degree and clinical curative effect of judgement for prostate cancer. Key words: Prostatic Neoplasms; Proteins